Breast Biopsy Devices Market Size, Share, and Trends

Breast Biopsy Devices Market (By Product: Biopsy Needles, Guidance Systems, Biopsy Tables, Localization Wires, Assay Kits, Liquid Biopsy Instruments, Others; By Guidance: Image-Guided Biopsy, Mammography-guided Stereotactic Biopsy, Ultrasound-guided Biopsy, MRI-guided Biopsy, Other Guidance Techniques, Liquid Biopsy, NGS-based Biopsy, PCR-based Biopsy, Microarray-based Biopsy; By Type) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

  • Last Updated : November 2022
  • Report Code : 2402
  • Category : Healthcare

The global breast biopsy devices market size was exhibited at USD 1 billion in 2022 and is projected to hit around USD 1.52 billion by 2032 with a registered CAGR of 4.3% during the forecast period 2023 to 2032.

Breast biopsy techniques employ medical instruments known as breast biopsy devices. A breast biopsy is a surgical procedure that removes tissue or fluid to be examined and checked for any illnesses. Under microscopes, the excised tissue is analyzed to see whether it contains cancer.

Breast Biopsy Devices Market Size 2023 To 2032

Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare

Key Takeaways

  • By product type, the image-guided biopsy segment is predicted to account for a sizeable portion.
  • By guidance, the liquid biopsy segment is anticipated to grow the most from 2023 to 2032.
  • By type, the fine-needle aspiration segment is predicted to have the highest share in 2022.
  • North America contributed the largest revenue share in the worldwide market in 2022.

Growth Factor

Once a patient has a cancer diagnosis, a biopsy is a medical examination to analyze and remove the malignant tissue from the body. To obtain tissue samples for the diagnosis of the condition, a biopsy is used. Skin biopsy, shave biopsy, fine needle aspiration, incision, excision biopsy core, and vacuum-assisted biopsy are only a few of the biopsy procedures used in the diagnosis of malignancies. The main factor driving the growth of the global Breast Biopsy Device Market is an increase in the incidence of breast cancer. The market is now growing due to the expansion of breast cancer screening programs as well as the surgical acceptance of minimally invasive breast biopsies.

The market is expanding as a result of technical improvements and advancements in breast biopsy instruments. However, the expensive cost of breast biopsy and its numerous negative side effects might limit market expansion. Vendor promotion possibilities have been made essential by the increased prevalence of breast cancer. Important market players focus on expanding their product ranges and winning approvals for their goods. To spread the word and raise awareness about cancer, there are several platforms, including conferences that may be used. 

Additionally, several public and private institutions sponsor and award grants to companies that develop novel goods with cutting-edge technology solutions to detect breast cancer in its early stages. These elements may have a major impact on market expansion throughout the anticipated term.

  • Market vendors are seeing tremendous potential for company expansion as a result of the increased incidence rate of breast cancer.
  • The population's growing preference for minimally invasive operations, which has a quicker recovery time and less discomfort, is driving the market's expansion.
  • The increase in financial and grant support for biomarker research also has an impact on the market's expansion.
  • Breast biopsy instruments' technical developments and advancements are promoting market expansion.

Breast Biopsy Devices Market Scope

Report Coverage Details
Market Size in 2023 USD 1.04 Billion
Market Size by 2032 USD 1.52 Billion
Growth Rate from 2023 to 2032 CAGR of 4.3%
Largest Market North America 
Fastest Growing Market Asia Pacific 
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered
  • By Product
  • By Guidance
  • By Type
Regions Covered
  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

 

Breast Biopsy Devices Market Dynamics

Key Market Drivers

Year to Year growth in the incidence of breast cancers

  • The market is expanding as a result of rising breast cancer incidence in women, particularly those over the age of 40, and raising awareness of breast cancer screening programs. The data states that in 2020, there would be an expected 48 000 non-invasive and 276 000 aggressive breast cancer cases in the United States. They also stated that in the United States, 1 in 8 women will likely acquire breast cancer at some point in their lives.
  • These untapped market prospects are anticipated to materialize with the introduction of technologically sophisticated, minimally invasive breast biopsy technologies. Additionally, increasing elderly female populations and increased global breast biopsy awareness are anticipated to accelerate the breast biopsy market's growth.

Key Market Challenges

Risks associated with the use of breast biopsy devices

  • The dangers associated with the operations will probably have a detrimental impact on the market for breast biopsy devices. The invasiveness of the method employed affects the risk level. Although surgical core techniques may be more precise and successful, they come with significant dangers. Additionally, between 60% and 80% of the biopsies taken are benign. Women are therefore advised to seek a second opinion before having any such surgical treatments due to such risks involved, which is anticipated to have a detrimental impact on market growth.

Key Market Opportunities

The burgeoning number of breast cancer patients

  • Over the past 40 years, there has been a sharp increase in the incidence of breast cancer in every part of the world. In addition, rising worldwide breast cancer rates have been linked to a rise in the adoption of western-style sexual and reproductive practices on a global scale. According to the American Cancer Society, breast cancer is the second-leading cause of cancer-related deaths among women worldwide. One in eight American women will ever get invasive breast cancer. In 2018, there were 63,960 new instances of non-invasive (in situ) breast cancer and more than 265,000 new cases of invasive breast cancer among women in the United States, according to the American Cancer Society and the National Cancer Institute. According to information provided by the Canadian Cancer Society, about 26,300 women in Canada received a breast cancer diagnosis in 2017, representing a 25% increase in cancer occurrences. Each year, Germany reports more than 70,000 newly diagnosed cases of breast cancer.

A rise in government initiatives coupled with an increase in cancer awareness screening programs

  • A biopsy is a confirming process that aids in early cancer/tumor diagnosis, which promotes quick recovery, increased survival, and a reduction in morbidity and death. A breast biopsy is advised by medical professionals for the early diagnosis of breast cancer. Numerous governmental and private organizations, commercial enterprises, and medical facilities are working on innovative initiatives to raise public awareness of breast cancer and the benefits of early detection on health. The Pink Chain Campaign in India is a large-scale initiative that began with raising awareness of breast cancer. Additionally, increasing R&D expenditure is expected to encourage market expansion. For instance, the National Cancer Research Institute (NCRI) reports that its partners funded cancer research to the tune of almost USD 750 million in 2018–19. Therefore, it is anticipated that these initiatives to raise awareness of early breast cancer detection and diagnosis will support breast biopsy systems, advancing market development.

Product Type Insights

Due to the rising popularity of image-guided procedures in both developed and developing countries as well as the development of cutting-edge and distinctive designs, the biopsy needles market is predicted to account for a sizeable portion of the breast biopsy market. Consider the tri-axial needle, which has a cutting needle on the exterior, a pincer needle on the outside, and a sharp style within. Healthcare professionals may cut through tissue without crushing it because of the needle's shape. Despite its unusual shape, the needle is clearly visible with CT and ultrasonography, which are frequently utilized for biopsy guidance.

Guidance Insights

The Guidance category with respect to liquid biopsy is anticipated to grow the most over the forecast period. A revolutionary technique that is broadening the range of cancer diagnostics is a liquid biopsy. The significant growth of the market may be attributed to the expanding use of cutting-edge NGS-based assays and droplet digital PCR technology for conducting liquid biopsies in the majority of developed nations. To bring new products to market, businesses in the sector are increasing their R&D spending. Thus, ongoing clinical trials and a prospective product pipeline will fuel additional market expansion.

Type Insights

This sector is divided into needle breast and open surgical biopsies according to kind. The first is further divided into vacuum-assisted core biopsy, core-needle aspiration, and both. Due mostly to an increase in demand for less invasive treatments, the fine-needle aspiration category is predicted to have the highest share in 2022. Contrarily, the less invasive vacuum-assisted core biopsy, which entails creating a tiny incision through which the needle is put, followed by sample collection using a vacuum-powered device, is predicted to expand at a high CAGR value throughout the projection period.

Regional Insights

North America accounted for the largest revenue share in the worldwide market in 2022, and it is anticipated that the region would continue to dominate the market during the forecast period. The U.S. and Canada, two of the region's biggest economies, are the main sources of income for the market value in the area. The prospective market for medical tourism in the area underpins the value of the prevailing regional market. 

Breast Biopsy Devices Market Share, By Region, 2022 (%)

Furthermore, Asia Pacific is anticipated to grow at the fastest rate from 2022 to 2030, according to projections. The rapidly developing nations in the area have invested in the building of healthcare infrastructure, which is promoting the market growth. China, the world's second-largest economy, is expected to expand at a CAGR of 13.1% between 2022 and 2030, with a target market size of US$620.6 million. Other major geographic markets include Japan and Canada, which are expected to increase at rates of 4.8% and 7.8%, respectively, between 2022 and 2030. Germany is expected to expand within Europe at a rate of growth of around 5.8% CAGR.  Additionally, as the diagnostic market in developing nations becomes more aware of breast biopsy procedures, businesses are able to invest in breast biopsy equipment in these developing markets. Rapid advancements in health technology in nations like China, India, and South Korea have prompted hospitals and other breast care facilities to make large expenditures in cutting-edge technologies (comprising liquid breast biopsy and vacuum-assisted biopsy devices, amongst others). For instance, Cytecare Hospital in Bengaluru, India, was acknowledged as the first hospital to offer 3D mammography (Digital Breast Tomosynthesis) to female patients. Since 3D Mammography creates many successive slides through the tissues using low concentrations of x-rays at various angles, it offers an advantage over 2D scans. The scans take 10 seconds, after which the computer receives the conclusions.

Recent Developments

In March 2019, Dune Medical Devices revealed the results of the first human test of their smart biopsy device. The smart Biopdy from Dune Medical is a continuous soft tissue biopsy device that provides electrical samples in real time using small key needle detectors. To enhance diagnosis and readout, these electrical pulses are compared to astronomical data. The in-man stage signals the start of a more involved, exhaustive clinical investigation aimed at identifying the precise tissue makeup of the breast.

Breast Biopsy Devices Market Companies

  • Cook Medical Incorporated
  • Becton, Dickinson and Company
  •  Devicor Medical Products Inc.
  • C.R. Bard, Inc., Hologic Inc
  • Argon Medical Devices
  • Planmed OY
  • Encapsule Medical Devices LLC
  • Ethicon Endo-Surgery (Johnson and Johnson)

Segment Covered in the Report

By Product

  • Biopsy Needles
  • Guidance Systems
  • Biopsy Tables
  • Localization Wires
  • Assay Kits
  • Liquid Biopsy Instruments
  • Others

By Guidance

  • Image-Guided Biopsy
  • Mammography-guided Stereotactic Biopsy
  • Ultrasound-guided Biopsy
  • MRI-guided Biopsy
  • Other Guidance Techniques
  • Liquid Biopsy
  • NGS-based Biopsy
  • PCR-based Biopsy
  • Microarray-based Biopsy

By Type

  • Needle Breast Biopsy
  • Core Needle Biopsy (CNB)
  • Fine Needle Aspiration Biopsy (FNAB)
  • Vacuum-assisted Biopsy (VAB)
  • Open Surgical Breast Biopsy
  • Excisional
  • Incisional
  • Liquid Breast Biopsy
  • Circulating Tumor Cells
  • Circulating Tumor DNA (CtDNA)
  • Other Biomarkers

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The global breast biopsy devices market size was accounted at USD 1 billion in 2022 and it is expected to reach around USD 1.52 billion by 2032.

The global breast biopsy devices market is poised to grow at a CAGR of 4.3% from 2023 to 2032.

The major players operating in the breast biopsy devices market are Cook Medical Incorporated, Becton, Dickinson and Company, Devicor Medical Products Inc., C.R. Bard, Inc., Hologic Inc, Argon Medical Devices, Planmed OY, Encapsule Medical Devices LLC, Ethicon Endo-Surgery (Johnson and Johnson).

The driving factors of the breast biopsy devices market are the global increase in women's susceptibility to mammary cancer, together with screenings and awareness campaigns launched in their favor.

North America region will lead the global breast biopsy devices market during the forecast period 2023 to 2032.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Breast Biopsy Devices Market 

5.1. COVID-19 Landscape: Breast Biopsy Devices Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Breast Biopsy Devices Market, By Product

8.1. Breast Biopsy Devices Market, by Product, 2023-2032

8.1.1 Biopsy Needles

8.1.1.1. Market Revenue and Forecast (2021-2032)

8.1.2. Guidance Systems

8.1.2.1. Market Revenue and Forecast (2021-2032)

8.1.3. Biopsy Tables

8.1.3.1. Market Revenue and Forecast (2021-2032)

8.1.4. Localization Wires

8.1.4.1. Market Revenue and Forecast (2021-2032)

8.1.5. Assay Kits

8.1.5.1. Market Revenue and Forecast (2021-2032)

8.1.6. Liquid Biopsy Instruments

8.1.6.1. Market Revenue and Forecast (2021-2032)

8.1.7. Others

8.1.7.1. Market Revenue and Forecast (2021-2032)

Chapter 9. Global Breast Biopsy Devices Market, By Guidance

9.1. Breast Biopsy Devices Market, by Guidance, 2023-2032

9.1.1. Image-Guided Biopsy

9.1.1.1. Market Revenue and Forecast (2021-2032)

9.1.2. Mammography-guided Stereotactic Biopsy

9.1.2.1. Market Revenue and Forecast (2021-2032)

9.1.3. Mammography-guided Stereotactic Biopsy

9.1.3.1. Market Revenue and Forecast (2021-2032)

9.1.4. MRI-guided Biopsy

9.1.4.1. Market Revenue and Forecast (2021-2032)

9.1.5. Other Guidance Techniques

9.1.5.1. Market Revenue and Forecast (2021-2032)

9.1.6. Liquid Biopsy

9.1.6.1. Market Revenue and Forecast (2021-2032)

9.1.7. NGS-based Biopsy

9.1.7.1. Market Revenue and Forecast (2021-2032)

9.1.8. PCR-based Biopsy

9.1.8.1. Market Revenue and Forecast (2021-2032)

9.1.9. Microarray-based Biopsy

9.1.9.1. Market Revenue and Forecast (2021-2032)

Chapter 10. Global Breast Biopsy Devices Market, By Type 

10.1. Breast Biopsy Devices Market, by Type, 2023-2032

10.1.1. Needle Breast Biopsy

10.1.1.1. Market Revenue and Forecast (2021-2032)

10.1.2. Core Needle Biopsy (CNB)

10.1.2.1. Market Revenue and Forecast (2021-2032)

10.1.3. Fine Needle Aspiration Biopsy (FNAB)

10.1.3.1. Market Revenue and Forecast (2021-2032)

10.1.4. Vacuum-assisted Biopsy (VAB)

10.1.4.1. Market Revenue and Forecast (2021-2032)

10.1.5. Open Surgical Breast Biopsy

10.1.5.1. Market Revenue and Forecast (2021-2032)

10.1.6. Excisional

10.1.6.1. Market Revenue and Forecast (2021-2032)

10.1.7. Incisional

10.1.7.1. Market Revenue and Forecast (2021-2032)

10.1.8. Liquid Breast Biopsy

10.1.8.1. Market Revenue and Forecast (2021-2032)

10.1.9. Circulating Tumor Cells

10.1.9.1. Market Revenue and Forecast (2021-2032)

10.1.10. Circulating Tumor DNA (CtDNA)

10.1.10.1. Market Revenue and Forecast (2021-2032)

10.1.11. Other Biomarkers

10.1.11.1. Market Revenue and Forecast (2021-2032)

Chapter 11. Global Breast Biopsy Devices Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Product (2021-2032)

11.1.2. Market Revenue and Forecast, by Guidance (2021-2032)

11.1.3. Market Revenue and Forecast, by Type (2021-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Product (2021-2032)

11.1.4.2. Market Revenue and Forecast, by Guidance (2021-2032)

11.1.4.3. Market Revenue and Forecast, by Type (2021-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Product (2021-2032)

11.1.5.2. Market Revenue and Forecast, by Guidance (2021-2032)

11.1.5.3. Market Revenue and Forecast, by Type (2021-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Product (2021-2032)

11.2.2. Market Revenue and Forecast, by Guidance (2021-2032)

11.2.3. Market Revenue and Forecast, by Type (2021-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Product (2021-2032)

11.2.4.2. Market Revenue and Forecast, by Guidance (2021-2032)

11.2.4.3. Market Revenue and Forecast, by Type (2021-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Product (2021-2032)

11.2.5.2. Market Revenue and Forecast, by Guidance (2021-2032)

11.2.5.3. Market Revenue and Forecast, by Type (2021-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Product (2021-2032)

11.2.6.2. Market Revenue and Forecast, by Guidance (2021-2032)

11.2.6.3. Market Revenue and Forecast, by Type (2021-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Product (2021-2032)

11.2.7.2. Market Revenue and Forecast, by Guidance (2021-2032)

11.2.7.3. Market Revenue and Forecast, by Type (2021-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Product (2021-2032)

11.3.2. Market Revenue and Forecast, by Guidance (2021-2032)

11.3.3. Market Revenue and Forecast, by Type (2021-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Product (2021-2032)

11.3.4.2. Market Revenue and Forecast, by Guidance (2021-2032)

11.3.4.3. Market Revenue and Forecast, by Type (2021-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Product (2021-2032)

11.3.5.2. Market Revenue and Forecast, by Guidance (2021-2032)

11.3.5.3. Market Revenue and Forecast, by Type (2021-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Product (2021-2032)

11.3.6.2. Market Revenue and Forecast, by Guidance (2021-2032)

11.3.6.3. Market Revenue and Forecast, by Type (2021-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Product (2021-2032)

11.3.7.2. Market Revenue and Forecast, by Guidance (2021-2032)

11.3.7.3. Market Revenue and Forecast, by Type (2021-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Product (2021-2032)

11.4.2. Market Revenue and Forecast, by Guidance (2021-2032)

11.4.3. Market Revenue and Forecast, by Type (2021-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Product (2021-2032)

11.4.4.2. Market Revenue and Forecast, by Guidance (2021-2032)

11.4.4.3. Market Revenue and Forecast, by Type (2021-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Product (2021-2032)

11.4.5.2. Market Revenue and Forecast, by Guidance (2021-2032)

11.4.5.3. Market Revenue and Forecast, by Type (2021-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Product (2021-2032)

11.4.6.2. Market Revenue and Forecast, by Guidance (2021-2032)

11.4.6.3. Market Revenue and Forecast, by Type (2021-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Product (2021-2032)

11.4.7.2. Market Revenue and Forecast, by Guidance (2021-2032)

11.4.7.3. Market Revenue and Forecast, by Type (2021-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Product (2021-2032)

11.5.2. Market Revenue and Forecast, by Guidance (2021-2032)

11.5.3. Market Revenue and Forecast, by Type (2021-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Product (2021-2032)

11.5.4.2. Market Revenue and Forecast, by Guidance (2021-2032)

11.5.4.3. Market Revenue and Forecast, by Type (2021-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Product (2021-2032)

11.5.5.2. Market Revenue and Forecast, by Guidance (2021-2032)

11.5.5.3. Market Revenue and Forecast, by Type (2021-2032)

Chapter 12. Company Profiles

12.1. Cook Medical Incorporated

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Becton, Dickinson and Company

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Devicor Medical Products Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. C.R. Bard, Inc., Hologic Inc

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Argon Medical Devices

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Planmed OY

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Encapsule Medical Devices LLC

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Ethicon Endo-Surgery (Johnson and Johnson)

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client